Total Payments
$119,615
2024 Payments
$67,878
Companies
38
Transactions
254
Medicare Patients
516
Medicare Billing
$157,768
Payment Breakdown by Category
Other$68,088 (56.9%)
Consulting$37,070 (31.0%)
Education$6,161 (5.2%)
Food & Beverage$5,986 (5.0%)
Travel$2,310 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $68,088 | 56 | 56.9% |
| Consulting Fee | $37,070 | 16 | 31.0% |
| Education | $6,161 | 3 | 5.2% |
| Food and Beverage | $5,986 | 168 | 5.0% |
| Travel and Lodging | $2,310 | 11 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $41,303 | 47 | $0 (2024) |
| GlaxoSmithKline, LLC. | $35,904 | 35 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,224 | 17 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $13,699 | 21 | $0 (2023) |
| Travere Therapeutics, Inc. | $7,526 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,404 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $460.16 | 9 | $0 (2024) |
| Amgen Inc. | $309.34 | 10 | $0 (2024) |
| CALLIDITAS THERAPEUTICS US INC. | $276.02 | 11 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $249.72 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,878 | 116 | Lilly USA, LLC ($41,303) |
| 2023 | $18,233 | 51 | GlaxoSmithKline, LLC. ($13,939) |
| 2022 | $10,852 | 35 | GlaxoSmithKline, LLC. ($5,744) |
| 2021 | $17,557 | 20 | Bayer HealthCare Pharmaceuticals Inc. ($8,966) |
| 2020 | $3,930 | 7 | GlaxoSmithKline, LLC. ($3,680) |
| 2019 | $605.55 | 9 | AstraZeneca Pharmaceuticals LP ($223.24) |
| 2018 | $457.51 | 10 | Keryx Biopharmaceuticals, Inc. ($147.31) |
| 2017 | $100.10 | 6 | Relypsa, Inc. ($34.33) |
All Payment Transactions
254 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $99.16 | General |
| 12/10/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: NEPHROLOGY | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $130.94 | General |
| 11/20/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/19/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.89 | General |
| 11/14/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 11/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $124.12 | General |
| 11/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $31.02 | General |
| 11/08/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $55.84 | General |
| Category: Nephrology | ||||||
| 11/04/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 11/01/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Nephrology | ||||||
| 10/28/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: Immunology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $965.00 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Diabetes | ||||||
| 10/14/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $91.67 | General |
| 10/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: Endocrinology | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $309.69 | General |
| 09/26/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $31.02 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 109 | 163 | $29,334 | $13,046 |
| 2022 | 4 | 58 | 82 | $14,791 | $6,563 |
| 2021 | 7 | 139 | 292 | $206,611 | $43,730 |
| 2020 | 8 | 210 | 565 | $324,110 | $94,429 |
Total Patients
516
Total Services
1,102
Medicare Billing
$157,768
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 38 | $7,828 | $3,620 | 46.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 56 | $7,896 | $3,471 | 44.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 35 | $7,070 | $3,264 | 46.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $6,400 | $2,660 | 41.6% |
| 81003 | Automated urinalysis test | Office | 2023 | 12 | 14 | $140.00 | $30.80 | 22.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 41 | $5,781 | $2,270 | 39.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 17 | $3,502 | $1,789 | 51.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $3,840 | $1,670 | 43.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 12 | $1,668 | $833.25 | 50.0% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 20 | 82 | $141,942 | $24,085 | 17.0% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 12 | 27 | $21,330 | $6,580 | 30.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 71 | $13,490 | $4,244 | 31.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 41 | $11,111 | $3,522 | 31.7% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 21 | 37 | $7,104 | $2,256 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 22 | $7,338 | $1,686 | 23.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 12 | $4,296 | $1,357 | 31.6% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 31 | 236 | $192,812 | $56,437 | 29.3% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2020 | 27 | 94 | $64,578 | $18,819 | 29.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 46 | 81 | $16,767 | $4,946 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 56 | $16,688 | $4,922 | 29.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 28 | 34 | $10,372 | $2,746 | 26.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 15 | 23 | $9,471 | $2,597 | 27.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $7,514 | $2,221 | 29.6% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 20 | 28 | $5,908 | $1,741 | 29.5% |
About Dr. Rajeev Raghavan, MD
Dr. Rajeev Raghavan, MD is a Nephrology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1851599740.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajeev Raghavan, MD has received a total of $119,615 in payments from pharmaceutical and medical device companies, with $67,878 received in 2024. These payments were reported across 254 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($68,088).
As a Medicare-enrolled provider, Raghavan has provided services to 516 Medicare beneficiaries, totaling 1,102 services with total Medicare billing of $157,768. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine
- Location Houston, TX
- Active Since 07/03/2007
- Last Updated 11/27/2020
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1851599740
Products in Payments
- JARDIANCE (Drug) $55,500
- BENLYSTA (Biological) $26,348
- Kerendia (Drug) $13,699
- LOKELMA (Drug) $306.96
- ACTHAR (Biological) $290.98
- Veltassa (Drug) $277.36
- TARPEYO (Drug) $276.02
- KRYSTEXXA (Biological) $264.83
- XARELTO (Drug) $206.70
- TAVNEOS (Drug) $174.39
- Auryxia (Drug) $170.31
- Critline - Monitors (Device) $152.49
- AVYCAZ (Drug) $128.75
- JYNARQUE (Drug) $103.08
- SOLIRIS (Drug) $100.00
- Renal - PrisMax System (Device) $97.59
- LUPKYNIS (Drug) $93.06
- SAMSCA (Drug) $61.20
- Fabhalta (Drug) $56.85
- Renal - PD (Device) $54.18
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Houston
Sreedhar Mandayam, M.d, M.D
Nephrology — Payments: $789,657
Nephrology $789,657
Dr. Christopher Kwoh, M.d, M.D
Nephrology — Payments: $420,843
Nephrology $420,843
Dr. Maher Bishara, M.d, M.D
Nephrology — Payments: $119,839
Nephrology $119,839
Dr. Horacio Adrogue, Md, MD
Nephrology — Payments: $102,891
Nephrology $102,891
Dr. Jaya Kala, Md, MD
Nephrology — Payments: $81,881
Nephrology $81,881
Dr. Kevin Erickson, M.d, M.D
Nephrology — Payments: $78,746
Nephrology $78,746